MX354479B - Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. - Google Patents

Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.

Info

Publication number
MX354479B
MX354479B MX2013014933A MX2013014933A MX354479B MX 354479 B MX354479 B MX 354479B MX 2013014933 A MX2013014933 A MX 2013014933A MX 2013014933 A MX2013014933 A MX 2013014933A MX 354479 B MX354479 B MX 354479B
Authority
MX
Mexico
Prior art keywords
antibody
nitrogen mustard
combination therapy
hodgkin
lymphoma
Prior art date
Application number
MX2013014933A
Other languages
English (en)
Spanish (es)
Other versions
MX2013014933A (es
Inventor
Rojkjaer Lisa
Winderlich Mark
Amersdorfer Jutta
Steidl Stefan
Krohn Susanne
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2013014933A publication Critical patent/MX2013014933A/es
Publication of MX354479B publication Critical patent/MX354479B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013014933A 2011-08-16 2012-08-14 Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno. MX354479B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US201261654097P 2012-06-01 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number Publication Date
MX2013014933A MX2013014933A (es) 2014-04-16
MX354479B true MX354479B (es) 2018-03-07

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014933A MX354479B (es) 2011-08-16 2012-08-14 Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.

Country Status (24)

Country Link
US (3) US20140255427A1 (https=)
EP (2) EP2744515B1 (https=)
JP (1) JP6184952B2 (https=)
KR (3) KR20200058583A (https=)
CN (1) CN103732252B (https=)
AU (1) AU2012296907B2 (https=)
BR (1) BR112013033919B1 (https=)
CA (2) CA2841875C (https=)
CY (1) CY1125122T1 (https=)
DK (1) DK2744515T3 (https=)
ES (1) ES2909722T3 (https=)
HR (1) HRP20220228T1 (https=)
HU (1) HUE058350T2 (https=)
IL (1) IL230293B (https=)
LT (1) LT2744515T (https=)
MX (1) MX354479B (https=)
PL (1) PL2744515T3 (https=)
PT (1) PT2744515T (https=)
RS (1) RS63238B1 (https=)
RU (1) RU2625222C2 (https=)
SG (1) SG10201606785UA (https=)
SI (1) SI2744515T1 (https=)
SM (1) SMT202200159T1 (https=)
WO (1) WO2013024097A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． 慢性リンパ球性白血病（ｃｌｌ）の処置
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) * 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
WO2017172981A2 (en) 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
RS62155B1 (sr) * 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CZ302070B6 (cs) * 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
JP2008519047A (ja) 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
KR20110111303A (ko) * 2009-01-16 2011-10-10 글락소스미스클라인 엘엘씨 벤다무스틴 및 항-ｃｄ２０ 항체의 조합을 이용한 암의 치료
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 ｃｄ20 항체의 복합 요법
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
US20240366756A1 (en) 2024-11-07
MX2013014933A (es) 2014-04-16
RU2014103492A (ru) 2015-09-27
EP2744515B1 (en) 2022-02-09
EP4062936A1 (en) 2022-09-28
AU2012296907B2 (en) 2017-01-05
KR20140064873A (ko) 2014-05-28
CY1125122T1 (el) 2024-12-13
SG10201606785UA (en) 2016-10-28
US20200353077A1 (en) 2020-11-12
PT2744515T (pt) 2022-05-19
SI2744515T1 (sl) 2022-05-31
IL230293B (en) 2019-01-31
JP6184952B2 (ja) 2017-08-23
NZ617770A (en) 2016-01-29
JP2014525926A (ja) 2014-10-02
SMT202200159T1 (it) 2022-05-12
DK2744515T3 (da) 2022-03-28
KR102115203B1 (ko) 2020-05-28
CA2841875A1 (en) 2013-02-21
KR20200058583A (ko) 2020-05-27
CN103732252B (zh) 2017-11-10
CA2841875C (en) 2021-11-02
WO2013024097A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
CN103732252A (zh) 2014-04-16
PL2744515T3 (pl) 2022-05-30
HUE058350T2 (hu) 2022-07-28
KR20190107749A (ko) 2019-09-20
BR112013033919B1 (pt) 2022-11-16
HRP20220228T1 (hr) 2022-05-13
EP2744515A1 (en) 2014-06-25
ES2909722T3 (es) 2022-05-10
LT2744515T (lt) 2022-04-25
BR112013033919A2 (pt) 2017-12-19
RU2625222C2 (ru) 2017-07-12
RS63238B1 (sr) 2022-06-30
US20140255427A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
PH12015500196B1 (en) Methods of treating a tauopathy
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
CA141065S (en) Dual c clip
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
IN2014KN01160A (https=)
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
HK1202877A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
GB201208362D0 (en) Fixing system
MX2022006154A (es) Combinaciones y sus usos.
CA141066S (en) Dual c clip
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
EP4268900A3 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MY166063A (en) Intravenous antiviral treatments
UY33207A (es) Métodos de preparación de tiazolidinas
UA60147U (ru) Способ лечения больных хроническим некалькулезным холециститом с сопутствующим ожирением
HK1227285A1 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
WO2013176667A3 (en) Maspin-based treatment and prevention of cancer

Legal Events

Date Code Title Description
FG Grant or registration